Spanish validation of Charlson index applied to prostate cancer

Comorbidity assessment is essential in the triage of care for men with prostate cancer (PC). The aim of this study was to validate the Spanish version of the revised Charlson index (RCI) in PC. 731 PC patients diagnosed from 1993 to 2008 were referred to our Radiation Oncology Department. The RCI classified patients into four categories RCI 0, RCI 1–2, RCI 3–4, and RCI 5 and higher. The Kaplan–Meier method and Cox proportional hazards modeling were used. We also analyzed the median age of patients who remained alive at the last control and those who died due to non-prostate cancer comorbidities. 636 patients were included median age: 70 years (44–85). The mean follow-up was 153.62 months, (6–288 months). Distribution of the D’Amico risk classification was 21%, 38.2%, and 40.8% for low, intermediate, and high risk, respectively. The RCI distribution categories were: 303 (46.7%) RCI 0, 102 (16%) RCI 1–2, 131 (20.6%) RCI 3–4, and 100 (15.7%) RCI 5 and higher. The probability of non-cause-specific mortality at 5 and 10 years was 2. 4% and 11.25% RCI 0, 3 and 14.1% RCI 1–2, 5.7% and 22.1% RCI 3–4, and 47% and 92% (RCI 5 and higher). The median age in the last control in patients alive or who had died by non-PC causes was 82.81 years (55.27–102). The RCI may be used to aid medical decision making in older Spanish men with PC, especially in those with a high RCI 5 and higher.